{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:33Z","timestamp":1791475533475,"version":"4.3.4"},"reference-count":88,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Eravacycline (ERV), formerly known as TP\u2010434, is a novel tetracycline (TET) antibiotic that exhibits in vitro activity against various gram\u2010positive, gram\u2010negative aerobic and anaerobic pathogens, including those exhibiting TET\u2010specific acquired resistance mechanisms. Similar to other TETs, it inhibits protein synthesis through binding to the 30S ribosomal subunit. Eravacycline was approved by the United States Food and Drug Administration (FDA) in August 2018 for the treatment of complicated intraabdominal infections (cIAIs) in adults following the Investigating Gram\u2010Negative Infections Treated with Eravacycline (IGNITE)1 and IGNITE4 phase III trials. In these two, double\u2010blind, multicenter clinical trials, ERV was proven noninferior in terms of clinical response in comparison to ertapenem and meropenem, respectively. Eravacycline was well tolerated with nausea, vomiting, and infusion site reactions being the most commonly reported adverse reactions. Clinicians now have ERV as a novel therapeutic option for the treatment of adults with intraabdominal infections, allergies to \u03b2\u2010lactam agents, <jats:italic>Clostridioides difficile<\/jats:italic>\u2010associated diarrhea, or if tolerability to other agents is a concern.<\/jats:p>","DOI":"10.1002\/phar.2366","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:13:37Z","timestamp":1579133617000},"page":"221-238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Evaluation of Eravacycline: A Novel Fluorocycline"],"prefix":"10.1002","volume":"40","author":[{"given":"Sara","family":"Alosaimy","sequence":"first","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda C.","family":"Abdul\u2010Mutakabbir","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razie","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C. J.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-0081","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"},{"name":"Department of Pharmacy Detroit Medical Center Detroit Michigan"},{"name":"Division of Infectious Diseases Department of Medicine School of Medicine Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2018.03.013"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1636"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir153"},{"key":"e_1_2_15_5_1","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"CDC","year":"2019"},{"key":"e_1_2_15_6_1","unstructured":"Centers for Disease Control and Prevention (CDC).Antibioticresistance threats in the United States 2013. Available fromhttp:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/arthreats-2013-508.pdf. Accessed March 2 2019."},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17042"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0198-x"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0239-0"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2092"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1622"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-12-22"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464010-00005"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00047.2010"},{"key":"e_1_2_15_18_1","first-page":"258","volume-title":"Antibacterial antibiotics. Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry","author":"Beale JM","year":"2011"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/op4000219"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-013-1100-7"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/29.3.245"},{"key":"e_1_2_15_23_1","unstructured":"XERAVA (eravacycline) [package insert]. Tetraphase Pharmaceuticals MA: Tetraphase Pharmaceuticals Inc.;2018."},{"key":"e_1_2_15_24_1","unstructured":"HornPT SutcliffeJA WalpoleSM et al.Pharmacokinetics safety and tolerability of a novel fluorocycline TP\u2010434 following multiple dose administration. [abstract no. 603 plus poster]. 49th Annual Infectious Diseases Society of America; 20\u201323 Oct2011; Boston."},{"key":"e_1_2_15_25_1","unstructured":"MooreJ.Clinical Pharmacology and Pharmacometrics Review. Eravacycline. NDA#211109. Tetraphase Pharmaceuticals Inc. Division of Anti\u2010 Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration;2018."},{"key":"e_1_2_15_26_1","unstructured":"YueCS SutcliffeJA ColucciP et al.Population pharmacokinetics modeling of TP\u2010434 a novel fluorocycline following single and multiple dose administration [abstract no. A1\u2010028 plus poster]. 50th annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep;2010Boston."},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00366-16"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00240-16"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00275-18"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.6b02442"},{"key":"e_1_2_15_31_1","unstructured":"SinghRSFN FalcaoNMS SutcliffeJ DerendorfH.Plasma protein binding of eravacycline in mouse rat rabbit cynomolgus monkey African green monkey and human using microdialysis. 5trd International Conference Anitmicrobial Agents Chemotherapy (ICAAC) abstr A\u2010015 2013 Sep 10. Denver CO ;2013."},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01810-18"},{"key":"e_1_2_15_33_1","unstructured":"LeightonA ZupanetsI BezuglaN et al.Broad\u2010spectrum fluorocycline TP\u2010434 has oral bioavailability in humans [poster P1509]. 21st European Congress of Clinical Microbiology and Infectious Diseases\/27th International Congress of Chemotherapy. Milan Italy. 7\u201310 May 2011."},{"key":"e_1_2_15_34_1","unstructured":"GrossmanTHOBW FyfeC SutcliffeJA et al.Eravacycline is potent against third generation cephalosporin and crabapenem resistant Enterobacteriaceae carbapenem\u2010resistantAcinetobacter baumanniiand has isolate specific bactericidal activity [abstract no. C1374 plus poster]. 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 5\u20139 September2013; Washington CC."},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00157-18"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04354-14"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-17"},{"key":"e_1_2_15_38_1","unstructured":"US Food and Drug Administration.Eravacycline injection products. FDA\u2010identifed interpretive criteria. Available fromhttp:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/ucm618563.htm. Accessed February 2019."},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04727-14"},{"key":"e_1_2_15_40_1","unstructured":"MorrisseyI SutcliffeJ HackelM HawserS et al.Assessment of eravacycline against a recent global collection of 4 462 Enterobacteriaceae clinical isolates (2013\u20132014) [abstract no. C619 plus poster]. 55th Annual Interscience Conferrence on Antimicrobial Agents and Chemotherapy; 17\u201321 September2015; San Diego CA."},{"key":"e_1_2_15_41_1","unstructured":"HuntD XiaoX ClarkR et al.TP\u2010434 is a novel broad\u2010spectrum fluorocycline [abstract no. 176 plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 September2010; Boston MA."},{"key":"e_1_2_15_42_1","doi-asserted-by":"crossref","unstructured":"MorrisseyI SutcliffeJ HackelM HawserS et al.Activity of eravacycline against north American and European Enterobacteriaceae including Multidrug\u2010Resistant Isolates Collected in 2013\u201314 [abstract no. 780 plus poster]. 53rd Infectious Diseases Society of America; 7\u201311 October2015; San Diego CA.","DOI":"10.1093\/ofid\/ofv133.497"},{"key":"e_1_2_15_43_1","unstructured":"MorrisseyI SutcliffeJ HackelM HawserS et al.Activity of eravacycline against anaerobic bacteria from Europe Collected in 2013\u201314 [abstract no. 784 plus poster]. 53rd Infectious Diseases Society of America; 7\u201311 October2015; San Diego CA."},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02206-17"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx147"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02403-15"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2018.06.016"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.73"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04967-14"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13"},{"key":"e_1_2_15_54_1","unstructured":"CarrA StringerJ.Antibiotic R&D Update: review of the antibiotic space. Needham & Company. Published on March 29 2019. Available fromhttps:\/\/needham.bluematrix.com\/sellside\/EmailDocViewer?encrypt=e0df6a7d-6477-4c25-9d2f-09f3fb40d31a&mime=pdf. Accessed June 26 2019."},{"key":"e_1_2_15_55_1","unstructured":"HackelM BouchillonS BiedenbachD SutcliffeJ.Comparative analysis of eravacycline (TP\u2010434) by broth microdilution and disk diffusion [abstract no. E\u20101180]. 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 10\u201013 September2013; Denver CO."},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00470-19"},{"key":"e_1_2_15_58_1","doi-asserted-by":"crossref","unstructured":"BasseresE MirandaJ Gonzales\u2010LunaA.In vitro activity of eravacycline a new tetracycline analog and comparators against the six most commonly isolated ribotyoes of clostridioides difficile [abstract no. 2398]. Infectious Diseases Society of America; 2\u20136 October 2019; Washington DC.","DOI":"10.1093\/ofid\/ofz360.756"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01058"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg050"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2270"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00648"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00993-09"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2000.6.277"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_2_15_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0141-y"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0258"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.19.5639-5644.2001"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.289-301.2005"},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0207"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01684-07"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409573200"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"e_1_2_15_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_2_15_75_1","unstructured":"XERAVA: Clinical Trials in Complicated Urinary Tract Infections: Tetraphase Official Responder. September 11 2018. Tetraphase MA."},{"key":"e_1_2_15_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00078-15"},{"key":"e_1_2_15_77_1","unstructured":"DitchK LawrenceK IzmailyanS et al.Eravacycline is effective in high\u2010risk complicated intra\u2010abdominal infection subgroups [abstract no. 75E plus poster]. MAD\u2010ID 8\u201011 May 2019; Orlando FL."},{"key":"e_1_2_15_78_1","unstructured":"TsaiL DasA MohrJ et al.Risk Factors for Change in Outcome Between the End of Therapy (EOT) and Post\u2010Treatment (PT) Evaluations in Patients with Complicated Urinary Tract Infections (cUTI) Treated with Eravacycline (ERV): analysis from a Randomized Double Blind Phase 3 Trial (IGNITE2). Poster 266. Poster presented at: ASM Microbe; June 16\u201020 2016; Boston MA."},{"key":"e_1_2_15_79_1","unstructured":"TsaiL ZervosM MillerL et al.Intravenous eravacycline with transition to oral therapy for treatment of complicated urinary tract infections (cUTI) including pyelonephritis: results from a randomized double\u2010blind multicenter phase 3 trial (IGNITE2). Poster 264. Poster presented at: ASM Microbe; June 16\u201320 2016; Boston MA."},{"key":"e_1_2_15_80_1","unstructured":"HornP RadcliffA RedicanS.Safety Tolerability and Pharmacokinetics of Single Intravenous Doses of TP\u2010271 a Novel Fluorocycline Antibiotic [Poster SUN\u2010198]. Presented at the 2017 American Society of Microbiology. New Orleans LA USA. June 1\u20135 2017."},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"e_1_2_15_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318053387f"},{"key":"e_1_2_15_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(80)90568-3"},{"key":"e_1_2_15_84_1","doi-asserted-by":"crossref","unstructured":"HornP RedicanS TsaiL.Impact of meal timing on eravacycline exposure during the oral portion of an IV to oral transition dosing regimen. Abstract 1832 October 4-8 2017.Infectious Diseases Society of America (IDSA):San Diego CA;2017.","DOI":"10.1093\/ofid\/ofx163.1362"},{"key":"e_1_2_15_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.08.005"},{"key":"e_1_2_15_86_1","unstructured":"KolkinS FonteA LawrenceK IzmailyanS.Effect of renal function in IGNITE 1 and IGNITE 4: two phase 3 studies to evaluate the efficacy and safety of eravacycline [abstract plus poster]. MAD\u2010ID; 12\u201315 May 8\u201311; Orlando FL."},{"key":"e_1_2_15_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp301"},{"key":"e_1_2_15_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis270"},{"key":"e_1_2_15_89_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.08.15"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:33Z","timestamp":1761050073000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1002\/phar.2366"],"URL":"https:\/\/doi.org\/10.1002\/phar.2366","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2020-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}